Entecavir: A New Nucleoside Analog for the Treatment of Chronic Hepatitis B Infection

  title={Entecavir: A New Nucleoside Analog for the Treatment of Chronic Hepatitis B Infection},
  author={Keri A. Sims and Abigail M. Woodland},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • Keri A. SimsA. Woodland
  • Published 1 December 2006
  • Medicine, Biology
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Background. Chronic hepatitis B infection carries considerable risk for the development of cirrhosis and hepatocellular carcinoma. Treatment options are increasing but are limited to interferon alfa‐2b, pegylated interferon alfa‐2a, lamivudine, adefovir dipivoxil, and entecavir. Entecavir, a nucleoside analog, is the newest oral antiviral approved in the United States for treatment of chronic hepatitis B. 

A Combination anti-HBV regimen using lamivudine and other agents in treatment of resistant chronic hepatitis B

The study concluded that the clinical benefit is apparent after a combination regimen using Lamivudine + Entecavir + Adefovir + Dipivoxil rather than  a combination  regimen  used to treat resistant hepatitis B, and recommended Optimal management of chronic hepatitis B.

Efavirenz in combination with n-acetyl cysteine shows improved outcome in treatment of hepatitis B

This study provides useful evidence that co-administration of N-acetyl cysteine with efavirenz protects the toxic effect of efvirenz, in patients with hepatitis B infection.

Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis

The nucleos(t)ide analogues are all effective for HBeAg seroconversion, H beAg loss, undetectable HBV DNA, and most are effective for ALT normalization in adults with CHB.

The HBV drug entecavir - effects on HIV-1 replication and resistance.

Caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens, and in vitro experiments showed that M184V confers resistance to entecvir.

Evaluation of 48-week response of treatment-naive chronic hepatitis B patients to 0.5 mg/day entecavir.

The 48-week entecavir treatment at a dose of 0.5 mg/day was shown to be effective both for HBeAg-positive and negative patients, and antiHBe seroconversion was seen in 2 of 91 patients, but the loss of HBsAg was never observed.

Clinical and Virological Response to Entecavir in HBV-Related Chronic Hepatitis or Cirrhosis: Data from the Clinical Practice in a Single-Centre Cohort

Entecavir represents an excellent therapy in patients with HBV-related liver disease and particularly with cirrhosis where it showed a good profile of tolerability, higher efficacy and an earlier virological response.

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

An overview of clinically available antiviral drugs for the primary care physician is provided, with a special focus on pharmacology, clinical uses, and adverse effects.



Drug Insight: nucleoside and nucleotide analog inhibitors for hepatitis B

  • S. FungA. Lok
  • Chemistry, Biology
    Nature Clinical Practice Gastroenterology &Hepatology
  • 2004
Details are provided into the benefits and limitations of lamivudine and adefovir dipivoxil for the treatment of chronic hepatitis B, which have similar antiviral efficacies.

Current treatment of chronic hepatitis B: benefits and limitations.

  • R. Perrillo
  • Biology, Medicine
    Seminars in liver disease
  • 2005
Much has been accomplished over the past decade, but much remains to be done in treating chronic hepatitis B, and the role for combination therapy remains unclear.

Entecavir: a potent new antiviral drug for hepatitis B

Data on entecavir therapy for treatment of nucleoside-naive, wild-type hepatitis B virus is being generated in Phase III clinical trials worldwide for both hepatitis B envelope antigen-positive and -negative subpopulations, as well as in lamivudine-resistant patients.

Clinical trial results of new therapies for HBV: implications for treatment guidelines.

  • R. Gish
  • Biology, Medicine
    Seminars in liver disease
  • 2005
The clinical experience with new antiviral agents and the implications of the trial results for practice guidelines are described, as well as several novel anti-HBV agents recently evaluated in phase II clinical trials.

Antiviral therapy for treatment-naïve hepatitis B virus patients.

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

This study showed that entecavir has potent antiviral activity against HBV at 0.1- mg/day and 0.5-mg/day doses, both of which were superior to lamivudine in chronically infected HBV patients.

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine, and the safety profile of the two agents is similar.

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

Peginterferon α‐2a (40 kDa) is superior to conventional interferonα‐2A in the treatment of chronic hepatitis C, and this is the first report on peginterferon β‐1a ( 40  kDa) in the Treatment of CHB.

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection

In this 28‐day study of entecavir a pronounced decrease of HBV DNA was observed and there were no significant side effects in entecvir patients in comparison with placebo‐treated patients.

A preliminary trial of lamivudine for chronic hepatitis B infection.

In a preliminary trial, 12 weeks of lamivudine therapy was well tolerated, and daily doses of 100 mg and 300 mg reduced HBV DNA to undetectable levels.